eligibility_summary
Inclusion: ≥18, refractory/relapsed solid tumor, mesothelin+ (IHC/ICC), ≥1 RECIST lesion, ECOG 0–1, life ≥3 mo, adequate organ/cardiac/pulmonary function, contraception if applicable. Exclusion: recent anti‑cancer or immunosuppressive therapy, vaccines/trials, pregnancy/lactation, active HBV/HCV/HIV/syphilis, unresolved ≥G2 AEs, prior allogeneic transplant or anti‑MSLN CAR‑T, recent/planned major surgery, unstable CNS mets, serious infection, cardiac, autoimmune, or bleeding, severe drug allergy, other recent cancer, serious neuropsychiatric illness, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05848999 tests UCLM802, an autologous anti-mesothelin CAR‑T cell therapy, in mesothelin-positive advanced solid tumors. Drug/intervention: genetically modified T cells expressing a chimeric antigen receptor targeting mesothelin, infused IV after lymphodepleting conditioning with fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent). Design includes dose-escalation/expansion and explores different conditioning regimens, administration modes, and optional combination with immune checkpoint inhibitors. Targets: mesothelin (MSLN) on tumor cells, mechanism is CAR-mediated recognition and T‑cell activation/cytotoxic killing of MSLN-expressing cells, with lymphodepletion to enhance CAR‑T expansion.